Prostate Cancer

  • In the battle against metastatic prostate cancer, the removal of lymph node metastases using image-guided surgery may have a high clinical impact on outcomes. Researchers at the 2017 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) demonstrated preclinically that...

  • In the featured article from the February 2017 issue of the Journal of Nuclear Medicine, researchers document the first-in-human application of a new imaging agent to help find prostate cancer in both early and advanced stages and plan treatment. The study indicates that the new agent — a...

  • An international group of researchers report success in mice of a method of using positron emission tomography (PET) scans to track, in real time, an antibody targeting a hormone receptor pathway specifically involved in prostate cancer. This androgen receptor pathway drives development and...

  • For men with intermediate-risk prostate cancer, radiation treatment with brachytherapy alone can result in similar cancer control with fewer long-term side effects. The findings come from research presented at the 58th annual meeting of the American Society for Radiation Oncology (ASTRO)...

  • The American Society for Radiation Oncology (ASTRO) announced the press program for its 58th Annual Meeting, Sept. 25-28 in Boston. The program includes multiple reports from phase III clinical trials, researchers from leading institutions in the United States and abroad, and examinations of a...

Synergy Radiology Associates Employs UroNav Fusion Biopsy System for Better Prostate Cancer Diagnosis
News | Biopsy Systems | July 17, 2017

July 17, 2017 — Radiologists from Synergy Radiology Associates (SRA) in Houston are using the power of 3-D medical...

Augmenix Announces First New Zealand Prostate Cancer Patient Treated with SpaceOAR Hydrogel
News | Patient Positioning Radiation Therapy | June 28, 2017

June 28, 2017 — Augmenix Inc. announced that the first patient in New Zealand has been treated with SpaceOAR...

A 77-year-old male with recurrent lymph node and pulmonary metastases detected by Ga-68 PSMA PET/CT but not by conventional imaging

A 77-year-old male with recurrent lymph node and pulmonary metastases detected by Ga-68 PSMA PET/CT but not by conventional imaging. Graphic courtesy of the Department of Nuclear Medicine, Royal North Shore Hospital, Sydney

News | Prostate Cancer | June 15, 2017

An estimated one in seven American men will be affected by...

Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer

IMAGE OF THE YEAR: Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer. Technology of dual-labeled PSMA-inhibitors for PET/CT imaging and fluorescence-guided intraoperative identification of metastases. This work might help to establish a new treatment regimen for more precise and sensitive pre-, intra- and post-therapeutic detection of prostate cancer.

Credit: Courtesy of A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center, Heidelberg, Germany; T. Simpfendörfer, B. Hadaschik, U. Haberkorn, Heidelberg University Hospital, Heidelberg, Germany; PET-image: Afshar-Oromieh et al., EJNMMI 2013; 40(4); STED-image: J. Matthias, German Cancer Research Center.

This study was supported by the VIP+ fund, Federal Ministry of Education & Research (BMBF), Germany.

Scientific Paper 531: “Preclinical evaluation of dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer.” A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center (DKFZ), Heidelberg, Germany; T. Simpfendörfer, B.  Hadaschik, U. Haberkorn, University Hospital, Heidelberg, Germany. Presented at SNMMI’s 64th Annual Meeting, June 10-14, 2017, Denver, Colo.

News | Prostate Cancer | June 15, 2017

In the battle against metastatic ...

Targeted MRI Could Pinpoint Aggressive Prostate Cancers Before They Spread

The ZD2-Gd probe, represented by the orange ball and green arrow, binds to the EDB-FN in the prostate cancer cells with high metastatic potential. This results in a strong MRI signal (upper right). Prostate cancer cells with low metastatic potential have no EDB-FN and so there is no MRI signal (lower right). Credit: Han, et al., Bioconjug Chem-Apr-2017

News | Prostate Cancer | May 24, 2017

May 24, 2017 — A research team funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) has...

FALCON Trial of Fluciclovine PET/CT Imaging Stops Recruitment after Successful Interim Analysis
News | Radiopharmaceuticals and Tracers | May 15, 2017

May 15, 2017 — Blue Earth Diagnostics announced that the Trial Steering Committee recommended further recruitment be...

News | Prostate Cancer | April 24, 2017

April 24, 2017 — Cancer Targeted Technology recently announced it is focusing on small molecules that target pivotal...

MRI

Multiparametric MRI (MpMRI) has proved helpful in enhancing biopsy sampling for prostate cancer when combined with ultrasound. 

Feature | Prostate Cancer | April 10, 2017 | By Jeff Zagoudis

While prostate cancer is one of the most common cancers among American men — the third leading cause of cancer...

News | Prostate Cancer | April 04, 2017

April 4, 2017 — Profound Medical Corp. announced that the first TULSA-PRO patient paid procedure has been...

Analogic, bkFusion, bk3000, MRI-ultrasound fusion, prostate biopsy, EAU 2017
News | Biopsy Systems | March 30, 2017

March 30, 2017 — Analogic Corp. announced that it will introduce its bkFusion solution for improving biopsy...

high-intensity focused ultrasound, HIFU, prostate tissue ablation, after radiotherapy, EDAP TMS SA, Ablatherm, British Journal of Urology International study
News | Focused Ultrasound Therapy | March 29, 2017

March 29, 2017 — EDAP TMS SA announced the publication of a peer-reviewed article that analyzed Ablatherm Robotic...

VERT, virtual environment radiotherapy, radiation therapy, patient anxiety, Thomas Jefferson University study
News | Radiation Therapy | March 27, 2017

March 27, 2017 — Radiation therapists and physicians know that education can reduce anxiety before radiation...

Karmanos Cancer Institute, UroNav Fusion Biopsy System, prostate cancer
News | Biopsy Systems | March 23, 2017

March 23, 2017 — Urology specialists at the Barbara Ann Karmanos Cancer Institute (Detroit) have begun using the...

News | Prostate Cancer | March 22, 2017

March 22, 2017 — Profound Medical Corp. announced that it has successfully completed the first sale of a TULSA-PRO...

Exact Imaging, Health Canada approval, ExactVu micro-ultrasound system, prostate biopsies, Sunnybrook Health Sciences Centre, Gregory Czarnota
News | Biopsy Systems | March 16, 2017

March 16, 2017 — Exact Imaging has received Health Canada approval and the corresponding medical device license (#...

PET/CT, recurrent prostate cancer, fluciclovine F-18, Emory University

CTVPOST (red) = CTVPRE (yellow) union CTVPET (pink). Also shown (upper right corner) are the PRE (square) vs POST (triangle) dose volume histograms for PTV1, PTV2, rectum, bladder, and penile bulb, showing minimal impact on target coverage or organs at risk dose with the modified targets. Image courtesy of Ashesh B. Jani, M.D., and David Schuster, M.D., Emory University.

News | Radiopharmaceuticals and Tracers | March 16, 2017

March 16, 2017 — The featured clinical investigation article of the March 2017 issue of the ...

Michigan Medicine, Prostate Cancer Risk Clinic, first in the U.S.
News | Prostate Cancer | March 09, 2017

March 9, 2017 — Michigan Medicine and the University of Michigan have launched the nation’s first prostate cancer...

prostate cancer, radiation therapy, high-dose-rate brachytherapy, HDR, Red Journal study

This is a single-fraction high-dose-rate prostate implant imaging and dosimetry. Image courtesy of Daniel Krauss/American Society for Radiation Oncology (ASTRO)

News | Brachytherapy Systems | March 06, 2017

March 6, 2017 — Results from a new prospective clinical trial indicate high-dose-rate (HDR)...

Accuray, CyberKnife system, SBRT, long-term disease control, prostate cancer, ASCO GU study
News | Radiation Therapy | February 17, 2017

February 17, 2017 — Accuray Inc. recently announced data from a prospective, Phase II, 17-center study which showed...

ayDCE software, mpMRI, multiparametric magnetic resonance imaging, prostate MRI, RSNA 2017, AHRA, SIIM
Technology | Magnetic Resonance Imaging (MRI) | February 13, 2017

February 13, 2017 —  aycan recently introduced ayDCE software powered by aycan workstation. The new software helps...

Overlay Init